TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21762225
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPI ASM8 (8 mg o.d.)
Study: 17348884
Drug: Transmucosal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmucosal implant placement (test group)
Study: 14732421
Drug: Social reinforcement
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social reinforcement of aftercare group therapy attendance
Study: 10066843
Drug: rtPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rtPA treatment
Study: 8148045
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both interventions)
Study: 3075625
Drug: Contralateral eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral eyes (no treatment)
Study: 21079818
Drug: Atorvastatin (ATO)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATO) 40 mg/day
Study: 15848518
Drug: Mixed chimerism
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed chimerism protocol with thymic transplantation of donor renal tissue, two donor-specific transfusions, low-intensity conditioning, and high-dose HSCT before renal transplantation.
Study: 6119042
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 400 microgram per day
Study: 6119042
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 200 microgram per day
Study: 6119042
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide (both dosages)
Study: 22614886
Drug: Deferred antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred antiretroviral therapy (ART)
Study: 24165392
Drug: ADM-facilitated one-stage
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADM-facilitated one-stage implant reconstruction
Study: 24165392
Drug: Two-stage tissue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage tissue expander/implant (TE/I) reconstruction
Study: 17005549
Drug: Azithromycin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.5% eye drops twice daily for 2 days
Study: 17005549
Drug: Azithromycin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.5% eye drops twice daily for 3 days
Study: 17005549
Drug: Azithromycin single
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin single 20 mg/kg oral dose
Study: 17005549
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (eye drops and oral)
Study: 15089820
Drug: Intravenous tyramine
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tyramine injections
Study: 11001599
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor therapy (donepezil)
Study: 9104896
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment at hospital admission
Study: 9104896
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists treatment at hospital admission
Study: 9104896
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers treatment at hospital admission
Study: 9104896
Drug: Combination anti-ischemic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination anti-ischemic therapy at hospital admission
Study: 9104896
Drug: Nitrates treatment
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates treatment at discharge
Study: 9104896
Drug: Combination anti-ischemic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination anti-ischemic therapy at discharge
Study: 9104896
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors treatment
Study: 9104896
Drug: Lipid-lowering agents
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering agents treatment
Study: 27067394
Drug: Sonidegib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 800 mg
Study: 24814043
Drug: Two 4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 4-hour interactive training sessions for nursing staff on appropriate medication treatment
Study: 15723732
Drug: Active 4-mg
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active 4-mg nicotine lozenge
Study: 15723732
Drug: Placebo (patch)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (patch)
Study: 15723732
Drug: Placebo (lozenge)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lozenge)
Study: 16025971
Drug: Combined internal-external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined internal-external therapy of TCM (internal administering of Chinese recipe and external applying of Fuxiong plaster)
Study: 16025971
Drug: Combined internal-external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined internal-external therapy of TCM
Study: 12844132
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg daily, 400 mg on day 1)
Study: 11111141
Drug: N(G)‐monomethyl‐L‐arginine (LNMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐L‐arginine (LNMMA) infused intracoronarily at 4, 8 and 16 micromol/min
Study: 11111141
Drug: N(G)‐monomethyl‐L‐arginine (LNMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐L‐arginine (LNMMA) infused intracoronarily
Study: 8806006
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (50 IU per dose)
Study: 1282615
Drug: Nisoldipine at
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine at a dose of 20 mg daily for 4 weeks
Study: 1282615
Drug: Beta-acetyldigoxin at
Normalized name: acetyldigoxins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-acetyldigoxin at a dose of 0.3 mg daily for 4 weeks
Study: 29138241
Drug: GH (2
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH (2 mg/day)
Study: 29138241
Drug: Combined GH
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined GH (2 mg/day) and testosterone (250 mg/week)
Study: 29138241
Drug: Testosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (250 mg/week)
Study: 27079660
Drug: Acetyl-L-carnitine (ALCAR)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALCAR) 3,000 mg/day orally for 2 months
Study: 24394686
Drug: Xylitol syrup
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol syrup (5 g, 3 times per day)
Study: 19616743
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy (HDRT)
Study: 19616743
Drug: Conventional-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose radiotherapy (CDRT)
Study: 8719263
Drug: Metoprolol (0.29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.29 mg kg‐1)
Study: 8719263
Drug: Propranolol (0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.28 mg kg‐1)
Study: 773081
Drug: Inderal 40
Normalized name: Inderal 40mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal 40 mg q.i.d.
Study: 773081
Drug: d-propranolol 40
Normalized name: propranolol hydrochloride 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-propranolol 40 mg q.i.d.
Study: 28224720
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide (3 × 60 mg/day for 14 days)
Study: 28224720
Drug: Fludrocortisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (1 × 0.2 mg/day for 14 days)
Study: 22782640
Drug: Golimumab with
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab with isoniazid for latent TB treatment
Study: 19221912
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing with a novice therapist in addition to treatment as usual (n=22)
Study: 19221912
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual alone (n=25)
Study: 1764954
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 micrograms once-daily
Study: 1764954
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micrograms twice-daily
Study: 6859504
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine + morphine sulphate 4 mg
Study: 6859504
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline + morphine sulphate 4 mg
Study: 27591991
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/day from day 1 for five consecutive days
Study: 27591991
Drug: Palonosetron and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron and dexamethasone in approved therapeutic dose from day 1 of chemotherapy
Study: 22649526
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered cognitive behavior therapy (ICBT)
Study: 19687128
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment plus applied behavioral analysis (N=32)
Study: 19687128
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment only (N=31)
Study: 17300303
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 20% human albumin solution administered over 120 seconds
Study: 17300303
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of furosemide intravenously along with albumin
Study: 15067419
Drug: All solutions
Normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All solutions tested
Study: 11199951
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with cognitive behavioral therapy
Study: 9894384
Drug: Conventional beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional beta-blockers
Study: 2806133
Drug: Injection Sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Sclerotherapy
Study: 30741103
Drug: modified Story
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Story Memory Technique (mSMT) training, twice per week for 5 weeks
Study: 31289068
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid suspension (intervention)
Study: 31289068
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy for another 5 days (control)
Study: 15635998
Drug: Standard chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chest physical therapy (CPT)
Study: 8353361
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 16.5 g of fish oil in 1500 ml (Impact)
Study: 31010445
Drug: Vortioxetine (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (flexible doses of 10/20 mg)
Study: 31010445
Drug: Escitalopram (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (flexible doses of 10/20 mg)
Study: 2669154
Drug: 2 gm
Normalized name: Algiderm 2 gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 gm of intravenous cefotetan after forceps delivery
Study: 30138014
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral therapy (ICBT)
Study: 30138014
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (GCBT) for children diagnosed with social anxiety disorder (SOC)
Study: 26888149
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban (60 mg)
Study: 26888149
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban (30 mg)
Study: 21585523
Drug: Naftazone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftazone (titrated up to 120 mg/day)
Study: 21067351
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent seasonal influenza vaccine (TIV)
Study: 14962151
Drug: Tramadol 37.5
Normalized name: ACETAMINOPHEN 325MG/TRAMADOL 37.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 37.5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP)
Study: 8130041
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 1 ml kg-1 + Clonidine 2 micrograms kg-1 in normal saline 1 ml (Group B)
Study: 8130041
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 1 ml kg-1 + Normal saline 1 ml (Group A)
Study: 1104655
Drug: Live, attenuated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated, influenza type A (H3N2) vaccine (Alice)
Study: 30064455
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid together with 10 × 106 cultured autologous bone marrow-derived MSCs (Low-dose)
Study: 30064455
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid together with 100 × 106 cultured autologous bone marrow-derived MSCs (High-dose)
Study: 28801071
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (REST)
Study: 18469276
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with oat and wheat bread and potato (high postprandial insulin response)
Study: 18469276
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with rye bread and pasta (low postprandial insulin response)
Study: 16563975
Drug: everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus 1.5 mg twice daily (n = 101)
Study: 16563975
Drug: azathioprine 1
Normalized name: azathioprine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: azathioprine 1 to 3 mg/kg/day (n = 112)
Study: 10349694
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ribavirin and rIFN-alpha 2b
Study: 7717480
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg.kg‐1 by intramuscular injection as premedication
Study: 2149533
Drug: Piroxicam 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 1% cream (38 patients)
Study: 12620603
Drug: Naloxone (opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (opioid antagonist)
Study: 9124664
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow at levels of 0.2-3 l.min-1
Study: 7957519
Drug: i.v. iopromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. iopromide 15 g iodine
Study: 7957519
Drug: i.v. iopromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. iopromide 80 g iodine
Study: 25439040
Drug: Allopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopathic treatment (usually paracetamol, 33.5%) and homeopathic treatment (Oscillococcinum, 56.6%)
Study: 25439040
Drug: Allopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopathic treatment
Study: 20018316
Drug: Escalating voltage
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating voltage treatment strategy (500 shocks at 14k V, 1,000 at 16 kV, and 1,000 at 18 kV)
Study: 20018316
Drug: Fixed voltage
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed voltage treatment strategy (2,500 shocks at 18 kV)
Study: 20018316
Drug: Escalating voltage
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating voltage treatment strategy
Study: 20018316
Drug: Fixed voltage
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed voltage treatment strategy
Study: 16864174
Drug: Anthracycline containing
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline containing chemotherapy
Study: 9661609
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) at an initial dose of 50 mg daily for 5 days, increased to 100 and 150 mg daily in subsequent cycles if no response was observed.
Study: 3743795
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) treatment
Study: 7655768
Drug: Maxil (Hikma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxil (Hikma Pharmaceuticals, 750 mg)
Study: 7655768
Drug: Zinacef (Glaxo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinacef (Glaxo, 750 mg)
Study: 2667318
Drug: Mixed-beam therapy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-beam therapy
Study: 766895
Drug: Insulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1 unit given intravenously)
Study: 7016781
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (100 mg three times per day)
Study: 25666740
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 µg)
Study: 25666740
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (10 IU)
Study: 19626807
Drug: Chlorhexidine for
Normalized name: CHLORHEXIDINE GLUCONATE 2 mg in 1 mL / KETOCONAZOLE 2 mg in 1 mL AURICULAR (OTIC) SOLUTION [Truseb Chlorhexidine for dogs, cats and Horses]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine for skin preparation (group 2)
Study: 19626807
Drug: Povidone Iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone Iodine for skin preparation (group 1)
Study: 17312207
Drug: bupivacaine 3
Normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 3 mg + fentanyl 20 mug
Study: 17312207
Drug: bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 7.5 mg
Study: 17312207
Drug: bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 5 mg + fentanyl 20 mug
Study: 17312207
Drug: bupivacaine 4
Normalized name: BUPIVACAINE 400MG/MELOXICAM 12MG/VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 4 mg + fentanyl 20 mug
Study: 12479490
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement intervention for depression treatment
Study: 15468432
Drug: Intramuscular ISG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ISG (4 mL every 2 months from unscreened donors)
Study: 7656524
Drug: Air as
Normalized name: OCTINOXATE 2010 mg in 30 mL / OCTOCRYLENE 900 mg in 30 mL / TITANIUM DIOXIDE 600 mg in 30 mL TOPICAL EMULSION [SHISEIDO SYNCHRO SKIN SELF-REFRESHING TINT 125 Fair Asterid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air as an insufflation agent
Study: 7656524
Drug: CO2 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 as an insufflation agent
Study: 2523493
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CTRX) 1 g once daily
Study: 2523493
Drug: Cefotiam (CTM)
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam (CTM) 2 g twice daily
Study: 28569122
Drug: Fingolimod combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod combined with bridging therapy (Alteplase and Mechanical Thrombectomy)
Study: 28569122
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy (Alteplase and Mechanical Thrombectomy) alone
Study: 28569122
Drug: Fingolimod combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod combined with bridging therapy
Study: 9871428
Drug: GI198745 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI198745 (0.1 to 40 mg)
Study: 57340
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of steroid drugs
Study: 325726
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of steroid drugs + 600 rads of radiotherapy to the graft
Study: 30759457
Drug: Nasal valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal valve lift treatment using absorbable, polylactic acid, self‐retaining cone threads (Silhouette Soft)
Study: 30759457
Drug: Nasal valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal valve lift treatment using absorbable, polylactic acid, self‐retaining cone threads (Silhouette Soft) + turbinoplasty